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Abstract 
Introduction 
The link between cardiovascular disease (CVD) and patients suffering from chronic 
inflammation is not clearly understood. We examined a knock-in mouse expressing a poly-
ubiquitin-binding-defective mutant of the protein ABIN1 (ABIN1(D485N)), which develops 
a systemic lupus erythematosus-like autoimmune disease due to the hyperactivation of IkB 
kinases (IKKs) and mitogen activated protein kinases (MAPK). These mice were used to 
determine the potential role of these signalling pathways in inflammation-mediated CVD 
development. 
Methods 
Laser Doppler imaging in combination with the iontophoresis of vasoactive chemicals were 
used to assess endothelium-dependent vasodilatation in vivo in ABIN1 (D485N)) mutant 
defective (n = 29) and wild-type (WT) control (n = 26) mice. Measurements were made at 
baseline and animals were subdivided to receive either chow or a pro-atherogenic diet for 4 
weeks, after which follow-up assessments were made. Paired and unpaired t-tests, ANOVA 
with post-hoc bonferroni correction were used for statistical significance P <0.05. 
Results 
Endothelium-dependent vasodilatation to acetylcholine was attenuated at four weeks in 
ABIN1(D485N)-chow fed mice compared with age-matched WT-chow fed mice (P <0.05). 
The magnitude of attenuation was similar to that observed in WT-cholesterol fed animals 
(versus WT-chow, P <0.01). ABIN1(D485N)-cholesterol fed mice had the poorest 
endothelium-dependent responses compared with other groups (P <0.001). ABIN1(D485N)-
chow fed mice had increased plasma interleukin-6 (IL-6) levels (versus WT-chow, P <0.001) 
and this was further elevated in ABIN1(D485N)-cholesterol fed mice (versus 
ABIN1(D485N)- chow P <0.05). IL-1alpha was significantly greater in all groups compared 
with WT-chow (P < 0.01). ABIN1(D485N) mice showed significant cardiac hypertrophy (P 
<0.05). 
Conclusions 
The ABIN(D485N) mice display endothelial dysfunction and cardiac hypertrophy, which is 
possibly mediated through IL-6 and to a lesser degree IL-1alpha. These results suggest that 
the ABIN1-mediated hyper-activation of IKKs and MAPKs might mediate chronic 
inflammation and CVD development. 
Introduction 
The role of inflammation in cardiovascular disease (CVD) is evident in patients suffering 
from chronic inflammatory conditions such as systemic lupus erythematous (SLE) [1] and 
rheumatoid arthritis (RA) [2], where the standardized mortality rate is higher [3] and 
probably due to accelerated atherosclerosis [4]. Patients who have RA or SLE show over-
expression for numerous pro-inflammatory cytokines including tumour necrosis factor (TNF) 
and C-reactive protein (CRP). Additionally, patients show significant leucocyte infiltration 
into the sub-endothelial space and have elevated levels of oxidative stress, which are key 
mediators of vascular dysfunction [5,6]. 
Significant disease associations have been shown between vascular function, high sensitive-
CRP (hs-CRP) and interleukin-6 (IL-6) in RA and SLE patients [7,8], suggesting a link 
between systemic cytokine over-expression and endothelial dysfunction, an early event in the 
development of CVD. Since the significant elevation in CVD risk in RA and SLE patients is 
not fully explained by traditional risk factors such as age, plasma cholesterol and tobacco 
smoking [9], there remains a need to better understand the mechanisms and underlying 
pathways that link chronic inflammatory diseases with increased CVD risk. 
There are numerous factors that drive inflammation, including nuclear factor kappa-B (NF-
κB). This transcription is activated by inflammatory stimuli and mediates the release of 
inflammatory molecules associated with atherosclerosis, including IL-6, IL-12 and TNF 
[10,11]. Activators of NF-κB include toll-like receptors (TLRs), endothelin-1, reactive 
oxygen species (ROS) and oxidised lipids [12,13], which through complex inflammatory 
pathways induce gene expression and are pro-atherogenic. 
Under basal conditions NF-κB is maintained in the cytoplasm in an inactive state through 
inhibitors of κB (IkB). Upon activation, IκB rapidly undergoes phosphorylation and 
degradation, inducing nuclear translocation and gene expression. The A20-binding inhibitors 
of NF-κB (ABINs1-3) are suppressors of inflammation. Recent work suggests that ABIN1 
restricts the activation of the canonical IKK complex and mitogen activated protein kinases 
(MAPK) by binding to Lys63-linked and Linear ubiquitin chains [14]. 
Human polymorphisms in the gene encoding the ABIN1 protein have been identified and are 
associated with a pre-disposition for autoimmune disease [15]. The clinical manifestations of 
polymorphisms in ABIN1 are wide spread and can resemble SLE [16,17]. Mutations in 
ABIN1 are associated with psoriasis, psoriatic arthritis and importantly in the context of 
CVD, He et al. [18] reported an enhanced risk of vasculitis. The TNIP1 (TNFAIP3-
interacting protein 1) gene locus that encodes for the protein ABIN1 is associated with the 
predisposition to SLE [19] is also thought to be significantly associated with other 
inflammatory mediated pathologies including coronary heart disease and myocardial 
infarction [20-22]. Wolfrum et al. [23] studied mice that were haploinsufficient for A20, a 
protein that interacts with ABIN1, and backcrossed them on to the CVD prone apolipoprotein 
E knock-out mouse. These mice showed significant exacerbation in atherosclerotic lesion 
presentation mediated through NF-κB activation [23]. 
The important roles of ABINs in physiology are highlighted in gene targeted knock-out mice 
that display organ failure and premature death [24]. We have previously reported on a knock-
in mouse in which wild-type ABIN1 was replaced by the polyubiquitin-binding-defective 
mutant ABIN1[D485N] [14]. Several types of immune cells from these mice show enhanced 
NF-κB and MAPK activation after TLR stimulation and display a SLE-like phenotype [14]. 
The ABIN1[D485N] knock-in mice show significant expansion of myeloid cells in various 
organs [14]. Caster et al. [15] reported similarity between the ABIN1[D485N] mice and SLE 
patients in the context of lupus nephritis, a leading cause of morbidity and mortality in 
chronic inflammation. The onset of CVD relevant to this mutation has not been addressed. 
We sought to establish the early cardiovascular consequences (before development of overt 
atherosclerosis and plaque formation) of an aberration in the homeostatic control of NF-κB 
and MAPK by studying the ABIN1[D485N] mutant. We assessed endothelial function as an 
early marker of CVD in-vivo, to better understand the link between modulators of 
inflammation and early development of CVD. 
Methods 
Mice 
The ABIN1[D485N] mice were originally described on a 129SvJxC57B/6 background [14]. 
Animals were subsequently backcrossed on a C57B/6 background for at least 8 generations. 
Mutant defective ABIN1[D485N] and wild-type (WT) mice utilised in these studies shared a 
common genetic background. 
Prior approval was obtained from the institutional ethical review committee (University of 
Dundee Ethical Review Committee) and experimental interventions were carried out by UK 
Home Office personal licence-holders under the authority of a Home Office project license. 
All mice were male. The ABIN1[D485N] mice were age matched to litter mate WT controls. 
Animals were transferred from a barrier breeding facility to the experimental facility (where 
the necessary equipment was installed), at least one week before vascular function testing, to 
allow acclimation and to avoid stress. 
Group allocations were randomly assigned as follows: WT control mice fed normal rodent 
chow (SDS R&M No.1) (n = 15), WT mice on a specifically tailored pro-atherogenic diet (n 
= 14) (TD.01383 diet, Harlan-Teklad), ABIN1[D485N] mice on rodent chow (n = 12) and a 
pro-atherogenic diet (n = 14). Researchers were blinded to genotypes in the group allocations 
throughout the study. 
Vascular responses 
Skin microvascular responses were measured in vivo at baseline (week 0) and 4 weeks later 
using laser Doppler imaging (LDI) and iontophoresis of vasoactive chemicals as described 
previously [25]. In brief, iontophoresis chambers were attached to the flanks of anaesthetised 
mice (Isoflurane in medical oxygen1.5-2% delivered via a nose cone) using double sided 
adhesive tape. 
Endothelium-dependent responses 
Baseline perfusion was normalised by pre-constriction using iontophoresis of a 1% solution 
of phenylephrine (PE) (Sigma-Aldrich). Following this, a 2% solution of the endothelium-
dependent vasodilator acetylcholine (ACh) (Sigma-Aldrich) was iontophoresed for 10 
minutes and the maximum vasodilatation measured by LDI. Perfusion was expressed in 
arbitrary perfusion units ± standard error (SE) and calculated using propriety software (Moor 
LDI software, version 5.2) as a percentage (%) change over baseline. 
Maximum vasodilator response to localised skin heating 
A skin heating probe (VPH3, Moor Instruments) with a total surface area of 3.2 cm2 was used 
to assess maximal dilator capacity. Baseline measurements of skin perfusion were taken for 5 
minutes, followed by localized heating of the skin to 44°C. 
Endothelium-independent responses 
Endothelium-independent vasodilatation was assessed at 4 weeks only using sodium 
nitroprusside (SNP) (Sigma-Aldrich) following a similar protocol to that for ACh. SNP was 
iontophoresed for 10 minutes. 
Plasma cholesterol analysis 
Plasma was used to quantify high density lipoprotein (HDL), low density and very low 
density lipoproteins (LDL/vLDL) fractions at week 4, using a colour metric assay (Abcam, 
Product code: ab655390) as detailed in the manufacture’s instructions. Results are expressed 
as mg/dl ± SE. 
Cytokine analysis 
Plasma was analysed using custom Bio-Plex® Pro kitsTM from BIO-RAD laboratories at 
baseline and 4 weeks for IL-1α, IL-6 and IL-10 as detailed in the manufacturer’s instructions. 
Results are expressed at pg/ml ± SE. 
Cardiac hypertrophy 
In cholesterol fed animals only cardiac hypertrophy was determined by calculating the ratio: 
total heart weight (mg)/ average length of tibia (mm). 
Statistical analysis 
Data are expressed as group means ± SE. Within and between group differences were 
compared using paired, unpaired t-tests and one-way ANOVA with post-hoc Bonferroni 
correction when significant differences were found. Associations between microvascular 
responses, plasma measures of cytokines, plasma cholesterol (LDL/vLDL and HDL), spleen 
mass and cardiac hypertrophy were tested using Pearson correlation coefficients in the 
software package PASW Statistic (Version 21). The null hypothesis was rejected at P < 0.05. 
Results 
Body weight 
Body weight increased in all groups over the study period and after four weeks feeding there 
were no significant differences amongst the different mouse groups (Figure 1). 
Figure 1 Body weight. (A) Body weights (study week 4) in WT-chow (n = 15), WT-
cholesterol (n = 14), ABIN1[D485N]-chow (n = 12) and ABIN1[D485N]-cholesterol (n = 14) 
fed mice. One-way ANOVA with post-hoc bon ferroni correction. Grams (g) ± SE. B: 
Summary of baseline measurements (study week 0). Baseline (12 weeks of age) plasma 
cytokines for IL-1α, IL-10 and IL-6 in WT (n = 10) and ABIN1[D485N] (n = 9) mice (pg/ml 
± SE). Microvascular responses in WT and ABIN1[D485N] animals: endothelium-dependent 
responses (WT n = 14, ABIN1[D485N] n = 10) and maximal dilator capacity (WT n = 17, 
ABIN1[D485N] n = 15) (%change ± SE). 
Study baseline data for plasma cytokines and vascular responses are summarised in Figure 
1B. 
Baseline cytokines 
Significant differences for baseline inflammatory markers were found between WT and 
ABIN1[D485N] mice. IL-1α was significantly greater in ABIN1[D485N] mice (WT 1376 ± 
42 pg/ml vs. ABIN1[D485N] 1658 ± 66 pg/ml, P < 0.01) as was anti-inflammatory IL-10 
(WT 213 ± 10 pg/ml vs. ABIN1[D485N] 335 ± 27 pg/ml, P < 0.001) (Figure 2A/B 
respectively). Levels of IL-6 were not significantly different between the groups (WT 1325 ± 
74 pg/ml vs. ABIN1[D485N] 1684 ± 267 pg/ml) (Figure 2C). 
Figure 2 Study baseline measurements. Baseline (12 weeks of age) plasma cytokines for 
(A) IL-1α (B) IL-10 and (C) IL-6 in WT (n = 10) and ABIN1[D485N] (n = 9) mice (pg/ml ± 
SE). Microvascular responses in WT and ABIN1[D485N] animals: (D) endothelium-
dependent responses (WT n = 14, ABIN1[D485N] n = 10) and (E) maximal dilator capacity 
(WT n = 17, ABIN1[D485N] n = 15) (%change ± SE). Unpaired Student’s T-test. **P < 
0.01, ***P < 0.001. 
Baseline vascular responses 
Baseline vascular responses were not significantly different between WT and 
ABIN1[D485N] mice for endothelium-dependent responses or maximal dilator capacity 
(ACh: WT 21 ± 3% change ABIN1[D485N] 24 ± 4%; maximal dilator capacity: WT 86 ± 
7% ABIN1[D485N] 92 ± 7%) (Figure 2D/E respectively). 
Plasma cholesterol 
Measurements of HDL cholesterol at 4 weeks showed that WT-chow (21 ± 2 mg/dl) fed mice 
had significantly greater HDL levels compared with ABIN1[D485N]-chow (2.0 ± 0.5 mg/dl, 
P < 0.001) and ABIN1[D485N]-cholesterol (2.0 ± 0.7 mg/dl, P < 0.001) fed mice (Figure 
3A). HDL levels were significantly greater in WT-cholesterol mice when compared with 
ABIN1[D485N]-chow (P < 0.001) and ABIN1[D485N]-cholesterol (P < 0.001) mice (Figure 
3A). 
Figure 3 Plasma cholesterol. Week 4 plasma levels of (A) high density lipoproteins (HDL) 
in WT-chow (n = 8), WT-cholesterol (n = 6), ABIN1[D485N]-chow (n = 9) and 
ABIN1[D485N]-cholesterol fed mice (n = 9) and (B) low density lipoproteins and very low 
density lipoproteins (LDL/vLDL) in the same animals (mg/dL ± SE). One-way ANOVA with 
post-hoc Bonferroni correction. *P < 0.05, **P < 0.01. ***P < 0.001. 
WT-cholesterol fed mice had significantly greater LDL/vLDL compared with the other 
groups (vs WT-chow P < 0.05, vs ABIN1[D485N]-chow P < 0.01, vs [D485N]-cholesterol P 
< 0.01) at 4 weeks (Figure 3B). 
Cytokines at 4-week follow-up 
Levels of IL-1α (1457 ± 49 pg/ml), IL-6 (1393 ± 53 pg/ml) and IL-10 (222 ± 9 pg/ml) did not 
change significantly in WT-chow fed mice over time compared with baseline values. 
Cholesterol feeding in WT mice significantly increased IL-1α (1659 ± 10 pg/ml) and IL-6 
(1726 ± 4 pg/ml,) compared with baseline values (P < 0.001, P < 0.001, respectively). IL-6 
and IL-1α were significantly greater in WT-cholesterol fed mice compared with age-matched 
WT-chow fed mice (Figure 4A/B respectively). There were no significant differences in IL-
10 between cholesterol fed WT mice (230 ± 11 pg/ml) and age matched WT-chow (Figure 
4C). Levels of IL-1α did not change significantly in ABIN1[D485N]-chow fed mice (1704 ± 
22 pg/ml), but remained significantly greater than age-matched WT-chow fed mice (P < 
0.001). Cholesterol feeding in ABIN1[D485N] mice did not result in a further significant 
change in IL-1α (1672 ± 8 pg/ml) (Figure 4A) but levels remained significantly greater than 
in age-matched WT-chow mice (P < 0.001). 
Figure 4 Follow up plasma cytokines. Plasma inflammatory markers at 4 weeks in WT-
chow (n = 10), WT-cholesterol (n = 7), ABIN1[D485N]-chow (n = 10) and ABIN1[D485N]-
cholesterol (n = 10) fed animals for (A) IL-1α, (B) IL-6 and (C) IL-10 (pg/ml ± SE). One-
way ANOVA with post-hoc Bonferroni correction *P < 0.05, **P < 0.01, ***P < 0.001. 
ABIN1[D485N]-chow fed animals displayed a significant increase in IL-6 compared with 
baseline values (1739 ± 21 pg/ml, P < 0.001). IL-6 at 4 weeks was significantly greater in 
ABIN1[D485N]-chow and ABIN1[D485N]-cholesterol fed mice compared with WT-chow 
(Figure 4B). ABIN1[D485N]-cholesterol fed mice had greater IL-6 levels compared with 
ABIN1[D485N]-chow (P < 0.05) (Figure 4B). 
Plasma measurements of IL-10 at 4 weeks did not significantly change in ABIN1[D485N] 
mice compared with baseline values. IL-10 levels remained significantly greater in 
ABIN1[D485N] mice compared with WT-chow and WT-cholesterol fed mice (Figure 4C). 
Vascular responses at 4-weeks 
Endothelium-dependent responses 
WT animals on normal rodent chow diet did not show significant changes in ACh-mediated 
vasodilatation over the study duration (baseline 22 ± 4% change vs 4 weeks 22 ± 4% change). 
WT mice fed a pro-atherogenic diet for 4 weeks showed a decrease in ACh-mediated 
vasodilatation compared with baseline values (baseline 20 ± 3% change vs 4 weeks 9 ± 2% 
change, P < 0.01) and WT age matched mice on rodent chow (P < 0.001). ACh-mediated 
vasodilatation in ABIN1[D485N]-chow (9 ± 2% change) fed mice were significantly 
attenuated compared with values at baseline (P < 0.001) and were significantly lower than 
age matched WT mice on a chow diet (P < 0.05) at 4 weeks, but were similar in magnitude to 
those observed in WT-cholesterol fed mice (Figure 5A). Cholesterol feeding in 
ABIN1[D485N] mice further attenuated ACh-mediated vasodilatation (0.03 ± 0.03% change) 
compared with age matched ABIN1[D485N]-chow fed mice (P < 0.001). ACh-mediated 
vasodilatation was significantly lower in ABIN1[D485N]-cholesterol fed animals compared 
with WT-chow (P < 0.001) and WT-cholesterol (P < 0.001) fed mice (Figure 5A). 
Figure 5 Follow up vascular function. Microvascular responses at 4 weeks to (A) 
endothelium-dependent acetylcholine in WT-chow (n = 11), WT-cholesterol (n = 11), 
ABIN1[D485N]-chow (n = 10) and ABIN1[D485N]-cholesterol (n = 10) fed mice and (B) 
endothelium-independent sodium nitroprusside in the same mice (%change ± SE). One-way 
ANOVA with post-hoc bonferroni correction. *P < 0.05, **P < 0.01, ***P < 0.001. 
Endothelium-independent responses 
At 4 weeks endothelium-independent responses were not significantly different amongst the 
groups (Figure 5B). 
Cardiac hypertrophy 
Significant differences for cardiac hypertrophy were found in ABIN1[D485N] mice (WT 7.1 
± 0.2 vs ABIN1[D485N] 8.2 ± 0.7, P < 0.05) (Figure 6A). 
Figure 6 Cardiac and spleen mass. (A) Cardiac hypertrophy measurements in WT (n = 14) 
and ABIN1[D485N] mice (n = 13) cholesterol fed mice: cardiac mass (mg) vs. tibia length 
(mm) ± SE (A). (B) spleen mass (g ± SE) in WT (n = 6) and ABIN1[D485N] (n = 7) 
cholesterol fed animals. Unpaired Student’s T-test. * P < 0.05, *** P < 0.001. C: Summary 
of follow up measurements: High density lipoproteins (HDL) in WT-chow (n = 8), WT-
cholesterol (n = 6), ABIN1[D485N]-chow (n = 9) and ABIN1[D485N]-cholesterol fed mice 
(n = 9) and low density lipoproteins and very low density lipoproteins (LDL/vLDL) in the 
same animals (mg/dL ± SE). Plasma inflammatory markers at 4 weeks in WT-chow (n = 10), 
WT-cholesterol (n = 7), ABIN1[D485N]-chow (n = 10) and ABIN1[D485N]-cholesterol (n = 
10) fed animals for (A) IL-1α, (B) IL-6 and (C) IL-10 (pg/ml ± SE). Microvascular responses 
at 4 weeks to endothelium-dependent acetylcholine in WT-chow (n = 11), WT-cholesterol (n 
= 11), ABIN1[D485N]-chow (n = 10) and ABIN1[D485N]-cholesterol (n = 10) fed mice and 
endothelium-independent sodium nitroprusside in the same mice (%change ± SE). Cardiac 
hypertrophy measurements in WT (n = 14) and ABIN1[D485N] mice (n = 13) cholesterol fed 
mice and spleen mass (g ± SE) in WT (n = 6) and ABIN1[D485N] (n = 7) cholesterol fed 
animals. Results are group means ± SE. 
Spleen weight 
Spleen mass was greater in cholesterol-fed ABIN1[D485N] mice (0.46 ± 0.02 g) compared 
with WT-cholesterol fed mice (0.14 ± 0.03 g) (P < 0.001) (Figure 6B). 
Follow-assessment of vascular responses and plasma cytokines, plasma cholesterol, 
measurements of cardiac hypertrophy and spleen weight are summarised in Figure 6C. 
Correlations 
There were no significant correlations between baseline vascular responses and plasma 
cytokines. Conversely significant associations were found at 4 weeks. ACh-mediated 
vasodilatation at 4 weeks correlated negatively with spleen mass (r = −0.722, P < 0.01) and 
with IL-1α (r = −0.0764, P < 0.01). HDL correlated negatively with IL-1α (r = −0.501, P < 
0.01) and IL-6 (r = −0.558, P < 0.001). 
Discussion 
Here we describe for the first time the onset of early CVD (endothelial dysfunction) in the 
polyubiquitin-binding-defective ABIN1[D485N] mice, a phenotype that is further 
exacerbated by cholesterol feeding. We found no significant differences in endothelium-
independent responses, suggesting that vascular smooth muscle activity was not 
compromised and indicates localised damage to the endothelium. We further report a 
significant reduction in plasma HDL of ABIN1[D485N] mice, an established risk factor for 
CVD. 
We have previously reported that ABIN1[D485N] mice have enhanced IKK and MAPK 
activity in B-cells, bone marrow derived macrophages and dendritic cells and display 
significant expansion of myeloid cells in spleen and lymph nodes [14]. Consequently, these 
mice bear a SLE-like phenotype as early as 3–4 months of age. Endothelial dysfunction is an 
early event in the development of CVD and we show in this study that it is present in 
ABIN1[D485N] mice at 4 months of age. Endothelial dysfunction was further exacerbated by 
dietary cholesterol showing elevated dysfunction when risk factors are combined (chronic 
inflammation and cholesterol). 
Selective inhibition of NF-κB from endothelial cells has been shown to be protective against 
atherosclerotic lesion formation in CVD prone apolipoprotein E knock-out mice [26]. Our 
data supports the notion that increase IKK activity, and hence increased NF-ĸB activation, 
has significant negative effects on the cardiovascular system. The activation of TLRs, in 
particular TLR-2 and TLR-4, is associated with atherogenesis whereas blockade of this 
signalling, achieved by amelioration of the myeloid differentiation primary response gene 88 
(MyD88), has shown atheroprotection [27]. Similarly the SLE phenotype of the 
ABIN1[D485N] mice is abrogated when they are expressed on a MyD88-deficient 
background [14], indicative of overlap in the signalling pathways involved in the 
development of SLE and CVD. 
We found a significant increase in IL-1α in plasma of ABIN1[D485N] mice at the study 
baseline, although there was no apparent difference in vascular responses between the two 
groups, suggesting that the relative differences and duration of change was not sufficient to 
impact on vascular function at this time point. The differences in inflammatory markers 
between ABIN1[D485N] and WT mice are presumably mediated by the hyperactivation of 
NF-ĸB and MAPKs. Commensal gut flora can activate TLRs and stimulate NF-ĸB [28,29] 
predisposing to chronic inflammation in ABIN1[D485N] mice. 
The exact mechanism responsible for the onset of endothelial dysfunction in ABIN1[D485N] 
mice requires further investigation; however this may be mediated by IL-6. We found a 
significant increase in IL-6 over time in ABIN1[D485N] mice, and this was further 
exacerbated by cholesterol feeding in ABIN1[D485N] mice, which displayed the poorest 
endothelium-dependent responses. IL-6 is an established cardiovascular risk factor [30,31]. 
Levels of IL-6 in WT-cholesterol mice at the end-point were similar to those observed in 
ABIN1[D485N]-chow mice, even though the latter group was not exposed to a major 
cardiovascular risk factor (cholesterol). A negative association between vascular responses 
and plasma levels of IL-6 has been described previously [32]. Taken together these data 
suggest that the mutation in ABIN1[D485N] mice predisposes to CVD in part via increasing 
levels of IL-6. 
IL-6 can inhibit activation of endothelial nitric oxide synthase (eNOS) and attenuate 
vasodilation by increasing the half-life of caveolin-1, resulting in more eNOS binding and 
reducing the bioavailability of NO [33]. NO is produced basally in the vascular system and 
maintains vascular tone. A loss in the bioavailability of NO is associated with diseases such 
as hypertension [34] and is regarded as an early phase of atherosclerotic plaque formation 
[35]. Importantly endothelial dysfunction mediated through NO loss is an early hallmark 
event in atherosclerotic plaque formation preceding vascular damage. The stimulated 
endothelium can express a number of vascular cell adhesion molecules and this in turn 
facilitates the movement of leukocytes into the arterial intima, a prerequisite for 
atherosclerotic plaque formation. 
We have previously reported that skin microvascular responses to ACh are mediated through 
the bioavailability NO and that this is diminished by cholesterol feeding in WT mice [25]. 
The loss of NO in the peripheral skin microcirculation increases total peripheral resistance. 
Reduced lumen diameter through attenuated vasodilatation (diminished NO bioavailability) 
can lead to development of left ventricular hypertrophy, an adaptive response to increased 
cardiac load (greater force is needed to pulsate blood through narrow arteries). This 
adaptation is essential for survival, and inhibition of cardiac hypertrophy in mice shows 
increased mortality through pressure overload and heart failure [36]. Thus, we conclude that 
cardiac hypertrophy in ABIN1[D485N]-cholesterol fed mice may be an adaptive response to 
diminished peripheral microvascular function. 
It is important to note that under pathophysiological conditions cytokines are released from 
numerous cell types, including activated endothelial cells. Stimulated endothelial cells 
express IL-1α. IL-1α is associated with CVD [37] and can contribute to atherosclerosis 
through the expression of cell adhesion molecules (vascular cell adhesion molecule-1 and 
intracellular adhesion molecule-1). Adhesion molecules are needed for the tethering of 
monocytes to the endothelial lining, for subsequent transmigration into the sub-endothelial 
space, an early phase in atherosclerotic plaque formation. 
Surprisingly, plasma levels of the anti-inflammatory IL-10 were significantly greater in 
ABIN1[D485N] mice, an unreported finding. The exact mechanism and significance of these 
remains unknown.. IL-10 can be synthesised by macrophages and attenuates pro-
inflammatory cytokine expression through a JAK/STAT3 pathway [38]. Forsberg et al. [39] 
have previously reported similar findings, showing increased levels of IL-10 in intra-
epithelial lymphocytes in the context of celiac disease. The ability to maintain these elevated 
levels of IL-10 are of particular interest and it needs to be established whether they can be 
sustained over a longer period of time (with greater age), and to establish whether ablation or 
sequestering of endogenous IL-10 in ABIN1[DN485] mice would further exacerbate the 
observed pathology in this and previous studies. 
IL-10 levels are anti-atherogenic, facilitating the uptake and efflux of cholesterol, which in 
turn is associated with reduced cell death and progression of atherosclerotic lesions [40]. This 
may in part explain why ABIN1[D485N]-cholesterol fed mice, despite being fed dietary 
cholesterol for 4 weeks, did not display elevated LDL/vLDL unlike WT-cholesterol fed mice. 
Pinderski et al. [41] have previously reported a lower plasma cholesterol level in animals 
over expressing IL-10 compared with both C57/B6 WT mice and homozygous IL-10 null 
animals fed cholesterol, although these observations were not statistically significant. In 
healthy individuals the efflux of cholesterol from the arterial intima is modulated by HDL 
and prevents lipid oxidation. Thus despite profound reductions in HDL ABIN1[D485N] mice 
may be able to efflux LDL/vLDL cholesterol through an IL-10-dependent mechanism to 
prevent significant accumulation in the blood stream. It remains unknown why the 
ABIN1[D485N] mutant defective mice show depleted levels of HDL in their plasma at 16 
weeks of age. It needs to be established whether cholesterol metabolism in these 
ABIN1[D485N] mice is affected primarily due to the mutant gene, or whether the progressive 
development of the SLE like phenotype in ABIN1[D485N] mice successively impacts 
significantly on plasma HDL levels. 
We aimed to establish a role for a mutation in ABIN1 in inflammatory-induced CVD 
development through assessment of endothelial function and measurement of systemic 
cytokine expression. Understanding the pathophysiological mechanisms and pathways 
responsible for early development of CVD in ABIN1[D485N] mice has potentially important 
clinical implications. The induction of chronic inflammation, endothelial dysfunction and 
cardiac hypertrophy by a single protein malformation highlights the need for selective 
therapeutic targets of inflammation to limit multi-organ disease, and the ABIN1 pathway 
might be one potential therapeutic target. Importantly, using a similar experimental approach 
in humans, we have previously shown that RA patients have attenuated endothelium-
dependent responses in the skin microcirculation, and that the degree of attenuation is related 
to the expression of systemic inflammatory cytokines [8], findings that are similar to those in 
the present study. Since endothelium-dependent responses in the microcirculation of the skin 
are indicative of defective coronary function [42] and future cardiovascular sequelae before 
clinical presentation [43], the findings from the present study point to a potentially important 
role for ABIN1 in the development and progression of inflammation-induced CVD. The 
findings in this study are in agreement with irregularities in the NF-ĸB pathway that have 
previously been implicated for the onset of CVD [18,20-22]. 
Conclusions 
In conclusion, we believe this to be the first in vivo observation to document the early 
development of CVD (endothelial dysfunction) as a result of a single protein mutation 
involved in NF-ĸB signalling, relevant to previously reported clinical genome wide 
association studies for SLE. Our data suggest that ABIN1 dysfunction could be 
mechanistically involved in the early development of inflammation-induced CVD risk. 
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